Cargando…

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey

BACKGROUND: The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire‐sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor defic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurer, M., Bork, K., Martinez‐Saguer, I., Aygören‐Pürsün, E., Botha, J., Andresen, I., Magerl, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Autoimmune Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587717/ https://www.ncbi.nlm.nih.gov/pubmed/30176179 http://dx.doi.org/10.1111/jdv.15232

Ejemplares similares

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
por: Aygören-Pürsün, Emel, et al.
Publicado: (2010)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Therapeutic trial in hereditary angioedema type III: Icatibant
por: Garro, Laila Sabino, et al.
Publicado: (2015)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
por: Aygören-Pürsün, Emel, et al.
Publicado: (2018)

Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history
por: Aygören-Pürsün, E, et al.
Publicado: (2013)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
por: Guilarte, Mar, et al.
Publicado: (2021)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
por: Williams, C L, et al.
Publicado: (2022)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Case report of treatment with Icatibant for recurrent throat swelling due to hereditary angioedema
por: Chung, Arthur G, et al.
Publicado: (2010)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
por: Nakajima-Kato, Yuko, et al.
Publicado: (2022)

A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
por: Cho, Somi, et al.
Publicado: (2022)

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage
por: Laragione, Teresina, et al.
Publicado: (2022)

CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients
por: Vandewalle, Julie, et al.
Publicado: (2023)

Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
por: Zhou, Liqing, et al.
Publicado: (2023)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
por: Aygören-Pürsün, Emel, et al.
Publicado: (2016)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_f3j694d341riifv0g2auc94knb